Sit Investment Associates Inc. Invests $423,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Sit Investment Associates Inc. purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 6,780 shares of the company’s stock, valued at approximately $423,000.

A number of other institutional investors have also added to or reduced their stakes in TMDX. Arizona State Retirement System grew its stake in shares of TransMedics Group by 1.9% during the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock worth $603,000 after buying an additional 184 shares during the last quarter. National Bank of Canada FI grew its position in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the last quarter. Quarry LP increased its holdings in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in TransMedics Group by 7.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company’s stock valued at $294,000 after purchasing an additional 317 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its stake in shares of TransMedics Group by 3.8% during the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after purchasing an additional 322 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the subject of several recent research reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Piper Sandler decreased their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, Robert W. Baird cut their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Price Performance

Shares of TMDX opened at $67.67 on Monday. The firm has a market cap of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business’s 50 day moving average price is $70.07 and its two-hundred day moving average price is $84.75.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.